Intersect ENT (Intersect ENT) GF Value : $23.33 (As of Apr. 26, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-26), Intersect ENT's share price is $28.24. Intersect ENT's GF Value is $23.33. Therefore, Intersect ENT's Price-to-GF-Value for today is 1.21.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Intersect ENT is Data Out of Date, Use Caution.

Intersect ENT (NAS:XENT) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Intersect ENT's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	28.24	/	23.33
	=	1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intersect ENT GF Value Related Terms

Thank you for viewing the detailed overview of Intersect ENT's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Intersect ENT (Intersect ENT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

1555 Adams Drive, Menlo Park, CA, USA, 94025

Website

https://www.intersectent.com

Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.

Executives

Elisabeth Sandoval	director	C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi	director	1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez	officer: Chief Human Resource Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick	officer: EVP, GC & Corporate Secretary	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West	director, officer: President and CEO	C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier	officer: EVP & Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr	officer: Vice President, Sales	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson	officer: Vice President, Marketing	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt	director, officer: See Remarks	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman	officer: General Counsel	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman	officer: Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski	officer: Chief Operations Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman	officer: See Remarks	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden	officer: Chief People Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025